GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of
automated, multiplex molecular diagnostic testing systems, today
announced the appointment of Lisa Giles, President and CEO of Giles &
Associates Consultancy, and Michael Kagnoff, a partner at DLA Piper
(US), to its Board of Directors. At the same time Steve Worland has
resigned from the Board.
“We are delighted to have Lisa and Mike join our Board. Their skill sets
are complementary to the deep operational and technical expertise of our
other directors and will benefit GenMark and our stockholders
immensely,” said Jim Fox, GenMark’s Chairman of the Board. “I would also
like to thank Steve Worland for his service and respect his recent
decision to resign from the Board to focus on his role as CEO and
President of eFFECTOR Therapeutics.”
About Lisa Giles
Ms. Giles has been the President and CEO of Giles & Associates
Consultancy since 2000, and CEO of Optivara, Inc. since 2013. Giles &
Associates is a privately held management consulting firm that
specializes in global strategy development, market intelligence and
business development transactions. The firm advises corporate boards,
CEOs and executive leadership teams on strategic direction, portfolio
optimization and monitoring performance. From 1996-2000, Ms. Giles was
Vice President of Strategy Development, at G.D. Searle & Company, where
she oversaw global pharmaceutical strategic planning, portfolio decision
analysis, portfolio optimization and transaction analysis. She
previously served as a member of the board of directors of Durata
Therapeutics, Inc., from August 2012 until its acquisition by Actavis
plc in November 2014.
Ms. Giles holds a B.S. from Juniata College and has completed Executive
Management Programs at both Stanford and the University of Chicago.
About Michael Kagnoff
Mr. Kagnoff has served as a partner at DLA Piper (US) since April 2008.
Prior to joining DLA Piper, he was a stockholder at Heller Ehrman LLP.
Mr. Kagnoff has been advising boards of directors of both public and
private companies for over 20 years, with a focus on life sciences and
technology companies. He has provided legal and business advice on a
range of topics, including strategic transactions, corporate governance,
and compensation matters.
Mr. Kagnoff received a B.A. and B.S. degree from the University of
Pennsylvania, and a J.D. from the University of California, Berkeley’s
Boalt Hall School of Law.
The appointments of Ms. Giles and Mr. Kagnoff were effective February 19th
2015. Each was appointed as a Class III director, with a term of
office expiring at the Company’s 2016 annual meeting of shareholders.
With their addition to the Board, Giles will become a member of the
Audit Committee and Kagnoff will become a member of the Corporate
Governance and Nominating Committee.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics is a leading provider of automated, multiplex
molecular diagnostic testing systems that detect and measure DNA and RNA
targets to diagnose disease and optimize patient treatment. Utilizing
GenMark’s proprietary eSensor® detection technology,
GenMark’s eSensor® XT-8 system is designed to support a broad
range of molecular diagnostic tests with a compact, easy-to-use
workstation and self-contained, disposable test cartridges. The eSensor®
detection technology is also incorporated into GenMark’s
sample-to-answer system, ePlex™. For more information, visit www.genmarkdx.com.
SAFE HARBOR STATEMENT
This press release includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating
results and financial position. Such statements, including, but not
limited to, those regarding the timely commercialization of our ePlex
system and the availability of future financing, are all subject to
risks and uncertainties that could cause our actual results and
financial position to differ materially. Some of these risks and
uncertainties include, but are not limited to, the future contributions
of our new Board members, our ability to successfully commercialize our
ePlex system and its related test menu in a timely manner, constraints
or inefficiencies caused by unanticipated acceleration and deceleration
of customer demand, our ability to successfully expand sales of our
product offerings outside the United States, and third-party payor
reimbursement to our customers, as well as other risks and uncertainties
described under the “Risk Factors” in our public filings with the
Securities and Exchange Commission. We assume no responsibility to
update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made.
Copyright Business Wire 2015